{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:46:54Z","timestamp":1773370014192,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82074298"],"award-info":[{"award-number":["82074298"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chengdu University of Traditional Chinese Medicine \u201cXinglin Scholars\u201d Enhancement Program","award":["QJJ2022011"],"award-info":[{"award-number":["QJJ2022011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02157-4","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:58:14Z","timestamp":1743731894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Decursin induces FLT3-ITD acute myeloid leukemia cell apoptosis by increasing the expression of the ubiquitin-conjugase UBE2L6"],"prefix":"10.1186","volume":"23","author":[{"given":"Tianxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Mou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqian","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2157_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11864-024-01202-7","volume":"25","author":"M Tecik","year":"2024","unstructured":"Tecik M, Adan A. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors. Curr Treat Options Oncol. 2024;25:719\u201351. https:\/\/doi.org\/10.1007\/s11864-024-01202-7.","journal-title":"Curr Treat Options Oncol"},{"key":"2157_CR2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532\u201342. https:\/\/doi.org\/10.1182\/blood-2002-02-0492.","journal-title":"Blood"},{"key":"2157_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5045\/br.2022.2022017","volume":"57","author":"JS Ahn","year":"2022","unstructured":"Ahn JS, Kim HJ. FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. Blood Res. 2022;57:32\u20136. https:\/\/doi.org\/10.5045\/br.2022.2022017.","journal-title":"Blood Res"},{"key":"2157_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079\u201389. https:\/\/doi.org\/10.1056\/NEJMoa1112304.","journal-title":"N Engl J Med"},{"key":"2157_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O\u2019Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Dohner K, Schlenk RF, Dohner H, Campbell PJ. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374:2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.","journal-title":"N Engl J Med"},{"key":"2157_CR6","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","volume":"114","author":"S Kayser","year":"2009","unstructured":"Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, Groner S, Spath D, Krauter J, Ganser A, Dohner H, Fischer T, Dohner K, German-Austrian AMLSG. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114:2386\u201392. https:\/\/doi.org\/10.1182\/blood-2009-03-209999.","journal-title":"Blood."},{"key":"2157_CR7","doi-asserted-by":"publisher","first-page":"e45765","DOI":"10.7759\/cureus.45765","volume":"15","author":"M Jalte","year":"2023","unstructured":"Jalte M, Abbassi M, El Mouhi H, Daha Belghiti H, Ahakoud M, Bekkari H. FLT3 Mutations in Acute Myeloid Leukemia: Unraveling the Molecular Mechanisms and Implications for Targeted Therapies. Cureus. 2023;15:e45765. https:\/\/doi.org\/10.7759\/cureus.45765.","journal-title":"Cureus."},{"key":"2157_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3324\/haematol.2009.013797","volume":"95","author":"S Park","year":"2010","unstructured":"Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D. Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95:819\u201328. https:\/\/doi.org\/10.3324\/haematol.2009.013797.","journal-title":"Haematologica"},{"key":"2157_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.21037\/sci.2017.05.04","volume":"4","author":"Y Chen","year":"2017","unstructured":"Chen Y, Pan Y, Guo Y, Zhao W, Ho WT, Wang J, Xu M, Yang FC, Zhao ZJ. Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. Stem Cell Investig. 2017;4:48. https:\/\/doi.org\/10.21037\/sci.2017.05.04.","journal-title":"Stem Cell Investig."},{"key":"2157_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/blood-2016-09-693648","volume":"129","author":"KW Pratz","year":"2017","unstructured":"Pratz KW, Levis M. How I treat FLT3-mutated AML. Blood. 2017;129:565\u201371. https:\/\/doi.org\/10.1182\/blood-2016-09-693648.","journal-title":"Blood"},{"key":"2157_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/10245332.2017.1415717","volume":"23","author":"Y Fan","year":"2018","unstructured":"Fan Y, Cao Y, Bai X, Zhuang W. The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia. Hematology. 2018;23:379\u201384. https:\/\/doi.org\/10.1080\/10245332.2017.1415717.","journal-title":"Hematology."},{"key":"2157_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith CC. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front Oncol. 2020;10: 612880. https:\/\/doi.org\/10.3389\/fonc.2020.612880.","journal-title":"Front Oncol"},{"key":"2157_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52: 100905. https:\/\/doi.org\/10.1016\/j.blre.2021.100905.","journal-title":"Blood Rev"},{"key":"2157_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.996438","volume":"12","author":"SS Ge","year":"2022","unstructured":"Ge SS, Liu SB, Xue SL. Developments and challenges of FLT3 inhibitors in acute myeloid leukemia. Front Oncol. 2022;12: 996438. https:\/\/doi.org\/10.3389\/fonc.2022.996438.","journal-title":"Front Oncol"},{"key":"2157_CR15","doi-asserted-by":"publisher","first-page":"17544","DOI":"10.1038\/s41598-018-35978-0","volume":"8","author":"L Gutierrez","year":"2018","unstructured":"Gutierrez L, Jang M, Zhang T, Akhtari M, Alachkar H. Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia. Sci Rep. 2018;8:17544. https:\/\/doi.org\/10.1038\/s41598-018-35978-0.","journal-title":"Sci Rep"},{"key":"2157_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1182\/bloodadvances.2019000919","volume":"4","author":"TC Tarver","year":"2020","unstructured":"Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations, Blood. Advances. 2020;4:514\u201324. https:\/\/doi.org\/10.1182\/bloodadvances.2019000919.","journal-title":"Advances"},{"key":"2157_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","volume":"10","author":"H Zhang","year":"2019","unstructured":"Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019;10:244. https:\/\/doi.org\/10.1038\/s41467-018-08263-x.","journal-title":"Nat Commun"},{"key":"2157_CR18","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/blood.2019000802","volume":"134","author":"YM Sun","year":"2019","unstructured":"Sun YM, Wang WT, Zeng ZC, Chen TQ, Han C, Pan Q, Huang W, Fang K, Sun LY, Zhou YF, Luo XQ, Luo C, Du X, Chen YQ. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression. Blood. 2019;134:1533\u201346. https:\/\/doi.org\/10.1182\/blood.2019000802.","journal-title":"Blood"},{"key":"2157_CR19","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1158\/1078-0432.CCR-12-3191","volume":"19","author":"X Huang","year":"2013","unstructured":"Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res. 2013;19:2355\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3191.","journal-title":"Clin Cancer Res"},{"key":"2157_CR20","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/nchembio.2486","volume":"13","author":"EL Weisberg","year":"2017","unstructured":"Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017;13:1207\u201315. https:\/\/doi.org\/10.1038\/nchembio.2486.","journal-title":"Nat Chem Biol"},{"key":"2157_CR21","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/leu.2010.114","volume":"24","author":"M Buchwald","year":"2010","unstructured":"Buchwald M, Pietschmann K, Muller JP, Bohmer FD, Heinzel T, Kramer OH. Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation. Leukemia. 2010;24:1412\u201321. https:\/\/doi.org\/10.1038\/leu.2010.114.","journal-title":"Leukemia"},{"key":"2157_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2019.03.046","volume":"453","author":"H Akiyama","year":"2019","unstructured":"Akiyama H, Umezawa Y, Ishida S, Okada K, Nogami A, Miura O. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress. Cancer Lett. 2019;453:84\u201394. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.046.","journal-title":"Cancer Lett"},{"key":"2157_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/2211-5463.12950","volume":"11","author":"RG Lopez-Reyes","year":"2021","unstructured":"Lopez-Reyes RG, Quinet G, Gonzalez-Santamarta M, Larrue C, Sarry JE, Rodriguez MS. Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3-ITD-driven acute myeloid leukemia. FEBS Open Bio. 2021;11:48\u201360. https:\/\/doi.org\/10.1002\/2211-5463.12950.","journal-title":"FEBS Open Bio"},{"key":"2157_CR24","first-page":"25","volume":"1","author":"H-J Chi","year":"1970","unstructured":"Chi H-J, Kim H-S. Studies on the Components of Umbelliferae Plants in Korea-Pharmacological Study of Decursin, Decursinol and Nodakenin, Korean. J Pharmacogn. 1970;1:25\u201332.","journal-title":"J Pharmacogn"},{"key":"2157_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1248\/yakushi1947.89.4_549","volume":"89","author":"K Hata","year":"1969","unstructured":"Hata K, Sano K. Studies on coumarins FR.om the root of Angelica decursiva FR et SAV.I. The structure of decursin and decursidin. Yakugaku Zasshi. 1969;89:549\u201357. https:\/\/doi.org\/10.1248\/yakushi1947.89.4_549.","journal-title":"Yakugaku Zasshi."},{"key":"2157_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00011-017-1114-7","volume":"67","author":"A Shehzad","year":"2018","unstructured":"Shehzad A, Parveen S, Qureshi M, Subhan F, Lee YS. Decursin and decursinol angelate: molecular mechanism and therapeutic potential in inflammatory diseases. Inflamm Res. 2018;67:209\u201318. https:\/\/doi.org\/10.1007\/s00011-017-1114-7.","journal-title":"Inflamm Res"},{"key":"2157_CR27","doi-asserted-by":"publisher","first-page":"13608","DOI":"10.18632\/aging.205343","volume":"15","author":"GH Lee","year":"2023","unstructured":"Lee GH, Lee HY, Lim YJ, Kim JH, Jung SJ, Jung ES, Chae SW, Lee J, Lim J, Rashid MMU, Min KH, Chae HJ. Angelica gigas extract inhibits acetylation of eNOS via IRE1alpha sulfonation\/RIDD-SIRT1-mediated posttranslational modification in vascular dysfunction. Aging. 2023;15:13608\u201327. https:\/\/doi.org\/10.18632\/aging.205343.","journal-title":"Aging."},{"key":"2157_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/pros.24482","volume":"83","author":"TA Bhat","year":"2023","unstructured":"Bhat TA, Dheeraj A, Nambiar DK, Singh SP, Yim DS, Singh RP. Decursin inhibits EGFR-ERK1\/2 signaling axis in advanced human prostate carcinoma cells. Prostate. 2023;83:534\u201346. https:\/\/doi.org\/10.1002\/pros.24482.","journal-title":"Prostate"},{"key":"2157_CR29","doi-asserted-by":"publisher","unstructured":"D. Kim, S.H. Go, Y. Song, D.K. Lee, J.R. Park, Decursin Induces G1 Cell Cycle Arrest and Apoptosis through Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress in Human Colorectal Cancer Cells in In Vitro and Xenograft Models, International Journal of Molecular Sciences, 25 (2024) https:\/\/doi.org\/10.3390\/ijms25189939.","DOI":"10.3390\/ijms25189939"},{"key":"2157_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bph.13408","volume":"173","author":"J Kim","year":"2016","unstructured":"Kim J, Yun M, Kim EO, Jung DB, Won G, Kim B, Jung JH, Kim SH. Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancers. Br J Pharmacol. 2016;173:1033\u201344. https:\/\/doi.org\/10.1111\/bph.13408.","journal-title":"Br J Pharmacol"},{"key":"2157_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ptr.4986","volume":"28","author":"JH Kim","year":"2014","unstructured":"Kim JH, Jung JH, Kim SH, Jeong SJ. Decursin exerts anti-cancer activity in MDA-MB-231 breast cancer cells via inhibition of the Pin1 activity and enhancement of the Pin1\/p53 association. Phytother Res. 2014;28:238\u201344. https:\/\/doi.org\/10.1002\/ptr.4986.","journal-title":"Phytother Res"},{"key":"2157_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3892\/ijmm_00000386","volume":"25","author":"WJ Kim","year":"2010","unstructured":"Kim WJ, Lee SJ, Choi YD, Moon SK. Decursin inhibits growth of human bladder and colon cancer cells via apoptosis, G1-phase cell cycle arrest and extracellular signal-regulated kinase activation. Int J Mol Med. 2010;25:635\u201341. https:\/\/doi.org\/10.3892\/ijmm_00000386.","journal-title":"Int J Mol Med"},{"key":"2157_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.canlet.2010.07.007","volume":"298","author":"Q Ahn","year":"2010","unstructured":"Ahn Q, Jeong SJ, Lee HJ, Kwon HY, Han I, Kim HS, Lee HJ, Lee EO, Ahn KS, Jung MH, Zhu S, Chen CY, Kim SH. Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells. Cancer Lett. 2010;298:212\u201321. https:\/\/doi.org\/10.1016\/j.canlet.2010.07.007.","journal-title":"Cancer Lett"},{"key":"2157_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2010.11.002","volume":"301","author":"HJ Kim","year":"2011","unstructured":"Kim HJ, Kim SM, Park KR, Jang HJ, Na YS, Ahn KS, Kim SH, Ahn KS. Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway. Cancer Lett. 2011;301:29\u201337. https:\/\/doi.org\/10.1016\/j.canlet.2010.11.002.","journal-title":"Cancer Lett"},{"key":"2157_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1158\/1538-7445.Am2023-8","volume":"83","author":"B John","year":"2023","unstructured":"John B, Sundaramoorthy P, Rainbolt E, Wong A, Ward Z, Avery J, Todd S, Kidder S, Gietl D, Hall C, Harris D. Abstract 8: Differential flt3 mutational status in acute myeloid leukemia predicts sensitivity to flt3 inhibitor gilteritinib in vitro and in vivo. Can Res. 2023;83:8\u20138. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-8.","journal-title":"Can Res"},{"key":"2157_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1158\/1535-7163.MCT-20-0663","volume":"20","author":"M Scarpa","year":"2021","unstructured":"Scarpa M, Singh P, Bailey CM, Lee JK, Kapoor S, Lapidus RG, Niyongere S, Sangodkar J, Wang Y, Perrotti D, Narla G, Baer MR. PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3beta-Mediated c-Myc and Pim-1 Proteasomal Degradation. Mol Cancer Ther. 2021;20:676\u201390. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0663.","journal-title":"Mol Cancer Ther"},{"key":"2157_CR37","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1182\/blood-2013-07-513044","volume":"122","author":"EI Zimmerman","year":"2013","unstructured":"Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013;122:3607\u201315. https:\/\/doi.org\/10.1182\/blood-2013-07-513044.","journal-title":"Blood"},{"key":"2157_CR38","doi-asserted-by":"publisher","first-page":"4199052","DOI":"10.1155\/2023\/4199052","volume":"2023","author":"Y Li","year":"2023","unstructured":"Li Y, Yuan Y, Yang L, Chen H, Zhang X, Wen T, Liao W, Zhao M, Zhao Z, Hu Q. AT7867 Inhibits the Growth of Colorectal Cancer Stem-Like Cells and Stemness by Regulating the Stem Cell Maintenance Factor Ascl2 and Akt Signaling. Stem Cells Int. 2023;2023:4199052. https:\/\/doi.org\/10.1155\/2023\/4199052.","journal-title":"Stem Cells Int"},{"key":"2157_CR39","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, Mody V, Choo EF, Dail M, Shah NP, Konopleva M, Sampath D, Lasater EA. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2021;106:1034\u201346. https:\/\/doi.org\/10.3324\/haematol.2019.244020.","journal-title":"Haematologica."},{"key":"2157_CR40","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Clin Cancer Res. 2019;25:6815\u201326. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0832.","journal-title":"Clin Cancer Res"},{"key":"2157_CR41","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.2021014241","volume":"140","author":"M Janssen","year":"2022","unstructured":"Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, Heid D, Renders S, Gollner S, Vierbaum L, Besenbeck B, Herbst SA, Knoll M, Kolb C, Przybylla A, Weidenauer K, Ludwig AK, Fabre M, Gu M, Schlenk RF, Stolzel F, Bornhauser M, Rollig C, Platzbecker U, Baldus C, Serve H, Sauer T, Raffel S, Pabst C, Vassiliou G, Vick B, Jeremias I, Trumpp A, Krijgsveld J, Muller-Tidow C, Dietrich S. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood. 2022;140:2594\u2013610. https:\/\/doi.org\/10.1182\/blood.2021014241.","journal-title":"Blood"},{"key":"2157_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107547","volume":"144","author":"S Wu","year":"2024","unstructured":"Wu S, Liu F, Gai Y, Carter J, Edwards H, Huttemann M, Wang G, Li C, Taub JW, Wang Y, Ge Y. Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML. Leuk Res. 2024;144: 107547. https:\/\/doi.org\/10.1016\/j.leukres.2024.107547.","journal-title":"Leuk Res"},{"key":"2157_CR43","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1182\/blood-2023-187725","volume":"142","author":"M Schwede","year":"2023","unstructured":"Schwede M, Rodriguez G, Henry S, Wood D, Mannis G, Majeti R, Chen J, Bendavid E, Zhang TY. The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data. Blood. 2023;142:958\u2013958. https:\/\/doi.org\/10.1182\/blood-2023-187725.","journal-title":"Blood"},{"key":"2157_CR44","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/hematology.2019000058","volume":"2019","author":"CC Smith","year":"2019","unstructured":"Smith CC. The growing landscape of FLT3 inhibition in AML. Hematology Am Soc Hematol Educ Program. 2019;2019:539\u201347. https:\/\/doi.org\/10.1182\/hematology.2019000058.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2157_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-022-00687-5","volume":"12","author":"SP Desikan","year":"2022","unstructured":"Desikan SP, Daver N, DiNardo C, Kadia T, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J. 2022;12:91. https:\/\/doi.org\/10.1038\/s41408-022-00687-5.","journal-title":"Blood Cancer J"},{"key":"2157_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02405-5","author":"M Halilovic","year":"2024","unstructured":"Halilovic M, Abdelsalam M, Zabkiewicz J, Lazenby M, Alvares C, Schmidt M, Brenner W, Najafi S, Oehme I, Hieber C, Zeyn Y, Bros M, Sippl W, Kr\u00e4mer OH. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-024-02405-5.","journal-title":"Leukemia"},{"key":"2157_CR47","doi-asserted-by":"publisher","first-page":"16428","DOI":"10.1021\/jacs.8b10320","volume":"140","author":"GM Burslem","year":"2018","unstructured":"Burslem GM, Song J, Chen X, Hines J, Crews CM. Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion. J Am Chem Soc. 2018;140:16428\u201332. https:\/\/doi.org\/10.1021\/jacs.8b10320.","journal-title":"J Am Chem Soc"},{"key":"2157_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216933","volume":"592","author":"Y Tan","year":"2024","unstructured":"Tan Y, Xin L, Wang Q, Xu R, Tong X, Chen G, Ma L, Yang F, Jiang H, Zhang N, Wu J, Li X, Guo X, Wang C, Zhou H, Zhou F. FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia. Cancer Lett. 2024;592: 216933. https:\/\/doi.org\/10.1016\/j.canlet.2024.216933.","journal-title":"Cancer Lett"},{"key":"2157_CR49","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41401-020-0455-x","volume":"42","author":"M Yu","year":"2021","unstructured":"Yu M, Fang ZX, Wang WW, Zhang Y, Bu ZL, Liu M, Xiao XH, Zhang ZL, Zhang XM, Cao Y, Wang YY, Lei H, Xu HZ, Wu YZ, Liu W, Wu YL. Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways. Acta Pharmacol Sin. 2021;42:604\u201312. https:\/\/doi.org\/10.1038\/s41401-020-0455-x.","journal-title":"Acta Pharmacol Sin"},{"key":"2157_CR50","doi-asserted-by":"publisher","first-page":"212","DOI":"10.18632\/oncotarget.27382","volume":"11","author":"CM Falvey","year":"2020","unstructured":"Falvey CM, O\u2019Donovan TR, El-Mashed S, Nyhan MJ, O\u2019Reilly S, McKenna SL. Correction: UBE2L6\/UBCH8 and ISG15 attenuate autophagy in esophageal cancer cells. Oncotarget. 2020;11:212. https:\/\/doi.org\/10.18632\/oncotarget.27382.","journal-title":"Oncotarget."},{"key":"2157_CR51","doi-asserted-by":"publisher","first-page":"41077","DOI":"10.18632\/oncotarget.6218","volume":"6","author":"X Zhou","year":"2015","unstructured":"Zhou X, Wei J, Chen F, Xiao X, Huang T, He Q, Wang S, Du C, Mo Y, Lin L, Xie Y, Wei L, Lan Y, Murata M, Huang G, Ernberg I, Matskova L, Zhang Z. Epigenetic downregulation of the ISG15-conjugating enzyme UbcH8 impairs lipolysis and correlates with poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2015;6:41077\u201391. https:\/\/doi.org\/10.18632\/oncotarget.6218.","journal-title":"Oncotarget."},{"key":"2157_CR52","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/15384101.2017.1403686","volume":"17","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Qiao L, Wang X, Ding C, Chen JJ. UHRF1 epigenetically down-regulates UbcH8 to inhibit apoptosis in cervical cancer cells. Cell Cycle. 2018;17:300\u20138. https:\/\/doi.org\/10.1080\/15384101.2017.1403686.","journal-title":"Cell Cycle."},{"key":"2157_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bcp.2016.12.022","volume":"128","author":"B Zhou","year":"2017","unstructured":"Zhou B, Li H, Xing C, Ye H, Feng J, Wu J, Lu Z, Fang J, Gao S. Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia. Biochem Pharmacol. 2017;128:12\u201325. https:\/\/doi.org\/10.1016\/j.bcp.2016.12.022.","journal-title":"Biochem Pharmacol"},{"key":"2157_CR54","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1096\/fj.06-8050com","volume":"22","author":"OH Kramer","year":"2008","unstructured":"Kramer OH, Muller S, Buchwald M, Reichardt S, Heinzel T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. FASEB J. 2008;22:1369\u201379. https:\/\/doi.org\/10.1096\/fj.06-8050com.","journal-title":"FASEB J"},{"key":"2157_CR55","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1080\/10428194.2020.1775212","volume":"61","author":"C Liang","year":"2020","unstructured":"Liang C, Peng CJ, Wang LN, Li Y, Zheng LM, Fan Z, Huang DP, Tang WY, Zhang XL, Huang LB, Tang YL, Luo XQ. Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD. Leukemia Lymphoma. 2020;61:2692\u20139. https:\/\/doi.org\/10.1080\/10428194.2020.1775212.","journal-title":"Leukemia Lymphoma."},{"key":"2157_CR56","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jnutbio.2009.02.009","volume":"21","author":"IF Lu","year":"2010","unstructured":"Lu IF, Hasio AC, Hu MC, Yang FM, Su HM. Docosahexaenoic acid induces proteasome-dependent degradation of estrogen receptor alpha and inhibits the downstream signaling target in MCF-7 breast cancer cells. J Nutr Biochem. 2010;21:512\u20137. https:\/\/doi.org\/10.1016\/j.jnutbio.2009.02.009.","journal-title":"J Nutr Biochem"},{"key":"2157_CR57","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305\u20139. https:\/\/doi.org\/10.1126\/science.1244917.","journal-title":"Science"},{"key":"2157_CR58","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/blood.2021011582","volume":"138","author":"K Lv","year":"2021","unstructured":"Lv K, Ren JG, Han X, Gui J, Gong C, Tong W. Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression. Blood. 2021;138:2244\u201355. https:\/\/doi.org\/10.1182\/blood.2021011582.","journal-title":"Blood"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02157-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:58:29Z","timestamp":1743731909000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02157-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2157"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02157-4","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Affiliated Hospital of Chengdu University of\u00a0Traditional Chinese Medicine (2023KZL-005), in line with the Declaration of Helsinki, and informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}